Physician profile
Moises Lustgarten
NPI 1518947324
$3,131.83
in general payments reported to CMS, 2019-2025
8 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.29 · 2020: $117 · 2021: $1,630 · 2022: $198 · 2023: $292 · 2024: $684 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,166.65 | 2019-2025 | Proclaim |
| Saluda Medical Americas, INC. | $449.71 | 2023-2024 | Evoke, Evoke Scs |
| Boston Scientific Corporation | $177.67 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Painteq LLC | $162.90 | 2024 | Painteq |
| Almatica Pharma LLC | $93.14 | 2021-2022 | |
| Masimo Corporation | $34.31 | 2023 | Set and Rainbow Set, Sedline |
| Vertex Pharmaceuticals Incorporated | $25.19 | 2024 | |
| Stimwave Technologies Incorporated | $22.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moises Lustgarten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.